Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens-Reference-Cited by-同舟云学术

Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens

Published:2018-03-15 Issue:11 Volume:57 Page:1399-1405
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Tängdén Thomas,Cojutti Pier Giorgio,Roberts Jason A.,Pea Federico

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-018-0638-5/fulltext.html

Reference17 articles.

1. Cvetković RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;5:859–78.

2. Lowance D, Neumayer HH, Legendre CM, et al. Valganciclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462–70.

3. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir agents for solid organ transplantation. J Clin Pharmacol. 1999;39:800–4.

4. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811–5.

5. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61:1153–83.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults;British Journal of Clinical Pharmacology;2024-06-18

2. Evidence supporting the use of therapeutic drug monitoring of ganciclovir in transplantation;Current Opinion in Infectious Diseases;2023-09-19

3. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring;Expert Review of Clinical Pharmacology;2023-02-23

4. Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients;Antimicrobial Agents and Chemotherapy;2023-02-23

5. Importance of antimicrobial stewardship in solid organ transplant recipients: An ESCMID perspective;Transplant Infectious Disease;2022-10